Correction: Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study

Affiliations

• ¹ Departments of Cutaneous Oncology and Sarcoma, Moffitt Cancer Center, Tampa, FL, USA. Jonathan.Zager@moffitt.org.
• ² Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, FL, USA. Jonathan.Zager@moffitt.org.
• ³ Thomas Jefferson University, Philadelphia, PA, USA.
• ⁴ European Institute of Oncology, IRCCS, Milan, Italy.
• ⁵ Departments of Cutaneous Oncology and Sarcoma, Moffitt Cancer Center, Tampa, FL, USA.
• ⁶ Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, FL, USA.
• ⁷ The University of Tennessee Health Science Center, Memphis, TN, USA.
• ⁸ The Ohio State University, Columbus, OH, USA.
• ⁹ University of South Alabama, Mobile, AL, USA.
• ¹⁰ Medical University of Graz, Graz, Austria.
• ¹¹ Charité Comprehensive Cancer Center, Berlin, Germany.
• ¹² Stanford University, Stanford, CA, USA.
• ¹³ Emory University, Atlanta, GA, USA.
• ¹⁴ Duke University, Durham, NC, USA.
• ¹⁵ University Hospital Würzburg, Würzburg, Germany.
• ¹⁶ University Hospital Marburg, Marburg, Germany.
• ¹⁷ University Hospital Zürich, Zürich, Switzerland.
• ¹⁸ Léon Bérard Center, Lyon, France.
• ¹⁹ Hospital Clínic Barcelona, Barcelona, Spain.
• ²⁰ Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
• ²¹ The Clatterbridge Cancer Center, University of Liverpool, Liverpool, UK.
• ²² University Hospital Regensburg, Regensburg, Germany.
• ²³ University Hospital Münster, Münster, Germany.
• ²⁴ Delcath Systems, Inc., Queensbury, NY, USA.
• ²⁵ University Hospital Southampton NHS Foundation Trust, Southampton, UK.